Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

被引:23
|
作者
Facchinetti, Fabrizio [1 ]
Civelli, Maurizio [1 ]
Singh, Dave [2 ]
Papi, Alberto [3 ]
Emirova, Aida [4 ]
Govoni, Mirco [4 ]
机构
[1] Corp Preclin R&D, Parma, Italy
[2] Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[3] Univ Ferrara, Dept Translat Med, Resp Med, Ferrara, Italy
[4] Global Clin Dev, Parma, Italy
关键词
phosphodiesterase 4 inhibitors (PDE4i); asthma; COPD-chronic obstructive pulmonary disease; inhaled administration; inflammation; SURFACTANT PROTEIN-D; METERED-DOSE INHALER; PHOSPHODIESTERASE-4; INHIBITOR; EOSINOPHILIC INFLAMMATION; PRECLINICAL PHARMACOLOGY; TRIPLE THERAPY; CYCLIC-AMP; ROFLUMILAST; COPD; CHF6001;
D O I
10.3389/fphar.2021.740803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease
    Page, Clive
    Cazzola, Mario
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44 (02) : 475 - 482
  • [32] Asthma and Chronic Obstructive Pulmonary Disease: Similarities and Differences
    Postma, Dirkje S.
    Reddel, Helen K.
    ten Hacken, Nick H. T.
    van den Berge, Maarten
    CLINICS IN CHEST MEDICINE, 2014, 35 (01) : 143 - +
  • [33] Roflumilast: A Novel Treatment for Chronic Obstructive Pulmonary Disease
    Reid, Debra J.
    Pham, Nga T.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (04) : 521 - 529
  • [34] The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease
    Cazzola, Mario
    Calzetta, Luigino
    Rogliani, Paola
    Matera, Maria Gabriella
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (07) : 733 - 744
  • [35] Asthma Masquerading as Chronic Obstructive Pulmonary Disease: A Study of Smokers Fulfilling the GOLD Definition of Chronic Obstructive Pulmonary Disease
    Al-Kassimi, Feisal A.
    Abba, Abdullah A.
    Al-Hajjaj, Mohammed S.
    Alhamad, Esam H.
    Raddaoui, Emad
    Shaikh, Shaffi Ahamed
    RESPIRATION, 2011, 82 (01) : 19 - 27
  • [36] Hydrogen sulfide as a novel biomarker of asthma and chronic obstructive pulmonary disease
    Suzuki, Yasuhito
    Saito, Junpei
    Munakata, Mitsuru
    Shibata, Yoko
    ALLERGOLOGY INTERNATIONAL, 2021, 70 (02) : 181 - 189
  • [37] The place of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease: a narrative review
    Andreeva-Gateva, Pavlina A.
    Stamenova, Eleonora
    Gatev, Tzvetelin
    POSTGRADUATE MEDICINE, 2016, 128 (05) : 474 - 484
  • [38] Disparities in Disease Burden and Treatment of Patients Asthma and Chronic Obstructive Pulmonary Disease
    Gaffney, Adam W.
    MEDICAL CLINICS OF NORTH AMERICA, 2022, 106 (06) : 1027 - 1039
  • [39] Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis
    Abdulrahim, Hunar
    Thistleton, Samuel
    Adebajo, Adewale O.
    Shaw, Tim
    Edwards, Christopher
    Wells, Alvin
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 1099 - 1108
  • [40] Effects of inhaled budesonide on insulin sensitivity in nondiabetic patients with asthma and chronic obstructive pulmonary disease
    Recep Canis
    Sevtap Sipahi Demirkok
    Zeynep Osar
    Huriye Balci
    Günay Can
    Advances in Therapy, 2007, 24 : 560 - 570